Should I buy or sell Alaunos Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alaunos Therapeutics in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" TCRT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TCRT, but not buy additional shares or sell existing shares. View TCRT analyst ratings or view top-rated stocks .

How have TCRT shares performed in 2024?

Alaunos Therapeutics' stock was trading at $1.0605 at the beginning of 2024. Since then, TCRT stock has increased by 5.6% and is now trading at $1.12. View the best growth stocks for 2024 here .

When is Alaunos Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our TCRT earnings forecast .

How were Alaunos Therapeutics' earnings last quarter?

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) issued its earnings results on Tuesday, November, 14th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.45) by $0.15.

When did Alaunos Therapeutics' stock split?

Alaunos Therapeutics's stock reverse split on Thursday, February 1st 2024. The 1-15 reverse split was announced on Thursday, February 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Alaunos Therapeutics?

Shares of TCRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:TCRT

Alaunos Therapeutics (TCRT) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free TCRT Stock Alerts

$1.12

-0.11 (-8.94%)

(As of 04/19/2024 ET)

Compare

Today's Range: $1.10
▼
$1.26
50-Day Range: $1.23
▼
$2.35
52-Week Range: $0.66
▼
$10.47

Volume: 49,707 shs
Average Volume: 195,530 shs
Market Capitalization: $17.93 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Alaunos Therapeutics alerts:

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Alaunos Therapeutics Stock (NASDAQ:TCRT)

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor engine. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas.

TCRT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TCRT Stock News Headlines

April 12, 2024 | seekingalpha.com

Revolution Medicines: An Expensive Shot At A Massive Market Opportunity

April 8, 2024 | investorplace.com

TCRT Stock Earnings: Alaunos Therapeutics Misses EPS for Q4 2023

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

April 1, 2024 | msn.com

Biora Therapeutics announces $6M registered direct offering and concurrent private placement

January 31, 2024 | msn.com

Alaunos Therapeutics Announces 1-for-15 Reverse Stock Split

January 31, 2024 | investing.com

Werewolf Therapeutics Inc (HOWL)

December 28, 2023 | benzinga.com

Alaunos Therapeutics Stock (NASDAQ:TCRT) Dividends: History, Yield and Dates

November 14, 2023 | benzinga.com

Recap: Alaunos Therapeutics Q3 Earnings

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

November 14, 2023 | investorplace.com

Why Is Alaunos Therapeutics (TCRT) Stock Up 14% Today?

November 14, 2023 | finance.yahoo.com

Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives

November 1, 2023 | morningstar.com

Alaunos Therapeutics Inc TCRT

August 15, 2023 | msn.com

Why Is Alaunos Therapeutics Sinking Today?

August 14, 2023 | finance.yahoo.com

Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives

June 29, 2023 | finance.yahoo.com

Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies

June 9, 2023 | benzinga.com

Alaunos Therapeutics Stock (NASDAQ:TCRT), Insider Trading Activity

May 26, 2023 | msn.com

Alaunos slips 17% on Phase 1/2 data for cancer cell therapy

May 25, 2023 | finance.yahoo.com

Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting

May 17, 2023 | uk.news.yahoo.com

One Alaunos Therapeutics Insider Raised Stake By 117% In Previous Year

May 15, 2023 | seekingalpha.com

Alaunos Therapeutics upgraded to buy at Wainwright on multiple catalysts

May 13, 2023 | finance.yahoo.com

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Q1 2023 Earnings Call Transcript

May 11, 2023 | marketwatch.com

8-K: Alaunos Therapeutics, Inc.

May 10, 2023 | finanznachrichten.de

Alaunos Therapeutics, Inc.: Alaunos Therapeutics Reports First Quarter 2023 Financial Results

May 10, 2023 | msn.com

Alaunos Therapeutics GAAP EPS of -$0.04 in-line

May 10, 2023 | msn.com

Recap: Alaunos Therapeutics Q1 Earnings

May 10, 2023 | finance.yahoo.com

Alaunos Therapeutics Reports First Quarter 2023 Financial Results

May 3, 2023 | finance.yahoo.com

Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023

See More Headlines

Receive TCRT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alaunos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/14/2023
Today: 4/19/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:TCRT
CUSIP: N/A
CIK: 1107421
Web: www.alaunos.com
Phone: (346) 355-4099
Fax: 617-241-2855
Employees: 1
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($2.3988)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-35,140,000.00
Net Margins: N/A
Pretax Margin: -702,800.00%
Return on Equity: -196.96%
Return on Assets: -134.81%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.22
Quick Ratio: 4.22

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.39 per share
Price / Book: 3.13

Miscellaneous

Outstanding Shares: 16,010,000
Free Float: 15,022,000
Market Cap: $19.54 million
Optionable: Optionable
Beta: -0.33

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Dale Curtis Hogue Jr. (Age 54)
Interim CEO & Director
Mr. Michael Wong (Age 44)
Vice President of Finance & Principal Accounting Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TCRT Stock Analysis - Frequently Asked Questions

Should I buy or sell Alaunos Therapeutics stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alaunos Therapeutics in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" TCRT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TCRT, but not buy additional shares or sell existing shares.
View TCRT analyst ratings or view top-rated stocks.
How have TCRT shares performed in 2024?: Alaunos Therapeutics' stock was trading at $1.0605 at the beginning of 2024. Since then, TCRT stock has increased by 5.6% and is now trading at $1.12.
View the best growth stocks for 2024 here.
When is Alaunos Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our TCRT earnings forecast.
How were Alaunos Therapeutics' earnings last quarter?: Alaunos Therapeutics, Inc. (NASDAQ:TCRT) issued its earnings results on Tuesday, November, 14th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.45) by $0.15.

When did Alaunos Therapeutics' stock split?: Alaunos Therapeutics's stock reverse split on Thursday, February 1st 2024. The 1-15 reverse split was announced on Thursday, February 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
How do I buy shares of Alaunos Therapeutics?: Shares of TCRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TCRT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Alaunos Therapeutics (TCRT) Stock Price, News & Analysis

About Alaunos Therapeutics Stock (NASDAQ:TCRT)

TCRT Stock Price History

TCRT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

TCRT Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info